Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin G. Drusano Clinical Microbiology and Infection

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

R. Leclercq Clinical Microbiology and Infection

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period J. Liñares, C. Ardanuy, R. Pallares, A.

Gut bacterial microbiota and obesity

D. Khalil, M. Hultin, M.U. Rashid, B. Lund

P. Clarke, S. Murchan, E.G. Smyth, H. Humphreys

Control of multidrug-resistant Gram-negative bacteria in low- and middle-income countries—high impact interventions without much resources N. Singh,

Penetration of fusidic acid and rifampicin into cerebrospinal fluid in low-grade inflammatory meningitis caused by Staphylococcus epidermidis A. Hedberg,

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

R. Cantón Clinical Microbiology and Infection

A.E. Muller, U. Theuretzbacher, J.W. Mouton

Louis Pasteur, from crystals of life to vaccination

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

Antimicrobial susceptibility of Streptococcus pneumoniae in Latin America: results from five years of the SENTRY Antimicrobial Surveillance Program M.

Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia C. Carbon, S. Moola,

How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach D. Guillemot Clinical Microbiology.

D.E. Low Clinical Microbiology and Infection

Vector control: a cornerstone in the malaria elimination campaign

Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations D. Andes, W.A. Craig Clinical Microbiology.

Oral versus intravenous therapy in the treatment of systemic mycosis

Training for the infectious diseases speciality in Norway

Community-acquired pneumonia: the evolving challenge

The use and therapeutic drug monitoring of teicoplanin in the UK

B. Gordts Clinical Microbiology and Infection

CMI editorial report 2011 Clinical Microbiology and Infection

Z. Wang, Z. Cui, Y. Li, T. Hou, X. Liu, Y. Xi, Y. Liu, H. Li, Q. He

Bacterial resistance—the clinical challenge

Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice J.E. Arends, P.A.M. Kracht, A.I.M. Hoepelman Clinical.

Elements of design: the knowledge on which we build

Changes in macrolide resistance among respiratory pathogens after decreased erythromycin consumption in Taiwan P.-R. Hsueh, J.-M. Shyr, J.-J. Wu Clinical.

Decreasing rates of resistance to penicillin, but not erythromycin, in Streptococcus pneumoniae after introduction of a policy to restrict antibiotic.

In vitro selection of antibiotic resistance in Pseudomonas aeruginosa

Levofloxacin in the treatment of ventilator-associated pneumonia

Metagenomics and probiotics

Effect of antioxidants on the immune response of Helicobacter pylori

Erythromycin susceptibility of viridans streptococci from the normal throat flora of patients treated with azithromycin or clarithromycin King A. , Bathgate.

B. Sádaba, J.R. Azanza, M.A. Campanero, E. García-Quetglas

W.A. Craig Clinical Microbiology and Infection

S8 – S47 and O50 – O440 Clinical Microbiology and Infection

Symposia and Oral Presentations

A. Bryskier Clinical Microbiology and Infection

J. Garau Clinical Microbiology and Infection

T.M. File Clinical Microbiology and Infection

Harmonised monitoring of antimicrobial resistance in Salmonella and Campylobacter isolates from food animals in the European Union S. Bronzwaer Clinical.

Antibacterial drug discovery in the 21st century

Grepafloxacin: pharmacokinetics and tissue penetration

Abstracts cont. Clinical Microbiology and Infection

Evaluation of 5-day therapy with telithromycin, a novel ketolide antibacterial, for the treatment of tonsillopharyngitis S.R. Norrby, J. Quinn, M. Rangaraju,

P.M. Hawkey Clinical Microbiology and Infection

Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci H.L. DuPont, Z.-D. Jiang Clinical Microbiology.

Reducing antibiotic use in influenza: challenges and rewards

Fibronectin concentrations in catheter sepsis

Antimicrobial drug development – the past, the present, and the future

An after-hours clinical liaison blood culture service—is it worth it?

Clinical Microbiology and Infection

Structure–activity relationships of ketolides vs. macrolides

Can pharmacokinetic–pharmacodynamic parameters provide dosing regimens that are less vulnerable to resistance? P. Courvalin Clinical Microbiology and.

Overview of cefixime use in community-acquired infections

The atypical pneumonias: clinical diagnosis and importance

Abstracts Clinical Microbiology and Infection

Modelling during an emergency: the 2009 H1N1 influenza pandemic

New oral cephalosporins in pediatric community-acquired infections

B.A. Cunha Clinical Microbiology and Infection

J.L. Balcázar Clinical Microbiology and Infection

G.C. Schito Clinical Microbiology and Infection

Joshua P. Metlay, Daniel E. Singer Clinical Microbiology and Infection

Impact of antibiotic restrictions: the patient's perspective

CMI readers' survey Clinical Microbiology and Infection

The future of diagnostic bacteriology

Presentation transcript:

Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin G. Drusano Clinical Microbiology and Infection Volume 7, Pages 24-29 (January 2001) DOI: 10.1046/j.1469-0691.2001.0070s3024.x Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions

Fig 1 Plasma concentration-time profile of telithromycin after single and 10 days' once-daily administration of 800 mg to 12 healthy young subjects [12]. ery-R, erythromycin resistant; ery-S, erythromycin susceptible; peni-R, penicillin resistant; LOQ, limit of quantification. Clinical Microbiology and Infection 2001 7, 24-29DOI: (10.1046/j.1469-0691.2001.0070s3024.x) Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions

Fig 2 Telithromycin plasma concentration-time profile following an oral 800 mg dose of telithromycin taken after either an overnight fast or a standard high-fat breakfast [14]. Clinical Microbiology and Infection 2001 7, 24-29DOI: (10.1046/j.1469-0691.2001.0070s3024.x) Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions

Fig 3 Mean concentration of telithromycin in epithelial lining fluid (ELF) and plasma following telithromycin 800 mg once daily for 5 days in 24 healthy volunteers [17]. Clinical Microbiology and Infection 2001 7, 24-29DOI: (10.1046/j.1469-0691.2001.0070s3024.x) Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions